We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CRL Stock to Gain From the Global Biotech Incubator Program Launch
Read MoreHide Full Article
Charles River Laboratories International, Inc. (CRL - Free Report) has launched the Charles River Incubator Program (“CIP”) via its Global Innovation Center of Excellence (CoE). The initiative is designed to support early-stage biotechnology companies in the discovery, development and phase-appropriate manufacturing of advanced therapies.
The latest development is expected to bolster the company’s Manufacturing Solutions segment. With this program, Charles River demonstrates a continued commitment to the global biotechnology industry by providing knowledge, connectivity and priority access to its portfolio.
Potential Trend of CRL Stock Following the News
After the announcement yesterday, Charles River shares fell by 3.9%, closing at $191.54. On a promising note, the Manufacturing segment continues to perform strongly across each of its businesses. The CDMO business is seeing strong client interest and booking activity within cell therapy, while the Biologics Testing business is thriving with high demand for core testing activities. The Microbial Solutions business also benefits from the demand for Endosafe testing consumables and improved instrument placements. We expect the latest development to positively boost the market sentiment toward CRL stock.
Charles River has a market capitalization of $10.19 billion. The company’s earnings yield of 5.1% compares favorably with the industry’s 3.15% yield. In the trailing four quarters, it delivered an average earnings surprise of 9.35%.
More on CRL’s New Program
Charles River’s established global Cell and Gene Therapy (CGT) Accelerator Program (CAP) accelerates advanced therapy developers 18-24 months from IND (Investigational New Drug) or CTA (Clinical Trial Application) submission. Building on its success, the CIP focuses on nurturing innovative start-up and early-stage biotechnology companies. The program’s goal is to form a strong foundation for commercial viability as its participants gain momentum with the goal of imparting cost-effective, consultative regulatory and quality expertise, personnel training initiatives, and enabling access to laboratory space and equipment.
Image Source: Zacks Investment Research
The Global Innovation CoE brings together a cross-functional team of scientific, regulatory and manufacturing experts in drug discovery, safety assessment, research models, clinical to commercial contract development, and manufacturing and microbial solutions. Based out of Charles River’s CDMO (contract development and manufacturing organization) CoE located in the Alderley Park campus, UK, the Global Innovation CoE is geared to foster and accelerate life sciences innovation, with enhanced access to life sciences and biotechnology experts.
Industry Prospects Favoring Charles River
Per a research report, the global biotechnology market was valued at $1.55 trillion in 2023 and is projected to grow at a compound annual rate of 13.96% through 2030. The market is driven by strong government support through initiatives aimed at the modernization of the regulatory framework, improvements in approval processes & reimbursement policies, as well as standardization of clinical studies.
More Developments in Charles River’s Manufacturing Unit
In October 2024, the company announced the launch of the Retrogenix Non-Human Protein Library, helping biopharmaceutical clients assess off-target binding to a non-human proteome to de-risk in vivo studies and aid in non-human species selection. The early insights are said to be generated without the lead time and expense associated with ex vivo tissue or in vivo research model studies, allowing clients to progress to safety studies, clinical trials and IND applications with highly relevant data.
CRL Stock Price Performance
In the past three months, Charles River shares have risen 1.8% against the industry’s 8.7% fall.
Penumbra shares have risen 8.8% in the past year. Estimates for the company’s 2024 earnings per share have jumped 0.7% to $2.81 in the past 30 days. PEN’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 10.54%. In the last reported quarter, it posted an earnings surprise of 23.19%.
Estimates for Haemonetics’ fiscal 2025 earnings per share have jumped 0.4% to $4.59 in the past 30 days. Shares of the company have decreased 3.1% in the past year against the industry’s growth of 21.1%. HAE’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 2.82%. In the last reported quarter, it delivered an earnings surprise of 2.75%.
Estimates for Phibro Animal Health’s fiscal 2025 earnings per share have increased 2.5% to $1.61 in the past 30 days. Shares of the company have surged 106.1% in the past year compared with the industry’s 21% rise. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 25.47%. In the last reported quarter, it delivered an earnings surprise of 52.17%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report predicting the 7 stocks that will soar highest in the coming month.
Image: Bigstock
CRL Stock to Gain From the Global Biotech Incubator Program Launch
Charles River Laboratories International, Inc. (CRL - Free Report) has launched the Charles River Incubator Program (“CIP”) via its Global Innovation Center of Excellence (CoE). The initiative is designed to support early-stage biotechnology companies in the discovery, development and phase-appropriate manufacturing of advanced therapies.
The latest development is expected to bolster the company’s Manufacturing Solutions segment. With this program, Charles River demonstrates a continued commitment to the global biotechnology industry by providing knowledge, connectivity and priority access to its portfolio.
Potential Trend of CRL Stock Following the News
After the announcement yesterday, Charles River shares fell by 3.9%, closing at $191.54. On a promising note, the Manufacturing segment continues to perform strongly across each of its businesses. The CDMO business is seeing strong client interest and booking activity within cell therapy, while the Biologics Testing business is thriving with high demand for core testing activities. The Microbial Solutions business also benefits from the demand for Endosafe testing consumables and improved instrument placements. We expect the latest development to positively boost the market sentiment toward CRL stock.
Charles River has a market capitalization of $10.19 billion. The company’s earnings yield of 5.1% compares favorably with the industry’s 3.15% yield. In the trailing four quarters, it delivered an average earnings surprise of 9.35%.
More on CRL’s New Program
Charles River’s established global Cell and Gene Therapy (CGT) Accelerator Program (CAP) accelerates advanced therapy developers 18-24 months from IND (Investigational New Drug) or CTA (Clinical Trial Application) submission. Building on its success, the CIP focuses on nurturing innovative start-up and early-stage biotechnology companies. The program’s goal is to form a strong foundation for commercial viability as its participants gain momentum with the goal of imparting cost-effective, consultative regulatory and quality expertise, personnel training initiatives, and enabling access to laboratory space and equipment.
Image Source: Zacks Investment Research
The Global Innovation CoE brings together a cross-functional team of scientific, regulatory and manufacturing experts in drug discovery, safety assessment, research models, clinical to commercial contract development, and manufacturing and microbial solutions. Based out of Charles River’s CDMO (contract development and manufacturing organization) CoE located in the Alderley Park campus, UK, the Global Innovation CoE is geared to foster and accelerate life sciences innovation, with enhanced access to life sciences and biotechnology experts.
Industry Prospects Favoring Charles River
Per a research report, the global biotechnology market was valued at $1.55 trillion in 2023 and is projected to grow at a compound annual rate of 13.96% through 2030. The market is driven by strong government support through initiatives aimed at the modernization of the regulatory framework, improvements in approval processes & reimbursement policies, as well as standardization of clinical studies.
More Developments in Charles River’s Manufacturing Unit
In October 2024, the company announced the launch of the Retrogenix Non-Human Protein Library, helping biopharmaceutical clients assess off-target binding to a non-human proteome to de-risk in vivo studies and aid in non-human species selection. The early insights are said to be generated without the lead time and expense associated with ex vivo tissue or in vivo research model studies, allowing clients to progress to safety studies, clinical trials and IND applications with highly relevant data.
CRL Stock Price Performance
In the past three months, Charles River shares have risen 1.8% against the industry’s 8.7% fall.
CRL’s Zacks Rank and Key Picks
Charles River carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Penumbra (PEN - Free Report) , Haemonetics (HAE - Free Report) and Phibro Animal Health (PAHC - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Penumbra shares have risen 8.8% in the past year. Estimates for the company’s 2024 earnings per share have jumped 0.7% to $2.81 in the past 30 days. PEN’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 10.54%. In the last reported quarter, it posted an earnings surprise of 23.19%.
Estimates for Haemonetics’ fiscal 2025 earnings per share have jumped 0.4% to $4.59 in the past 30 days. Shares of the company have decreased 3.1% in the past year against the industry’s growth of 21.1%. HAE’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 2.82%. In the last reported quarter, it delivered an earnings surprise of 2.75%.
Estimates for Phibro Animal Health’s fiscal 2025 earnings per share have increased 2.5% to $1.61 in the past 30 days. Shares of the company have surged 106.1% in the past year compared with the industry’s 21% rise. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 25.47%. In the last reported quarter, it delivered an earnings surprise of 52.17%.